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ABSTRACT: Protein−protein interactions (PPIs) play an important
role in numerous biological processes such as cell-cycle regulation and
multiple diseases. The family of 14-3-3 proteins is an attractive target
as they serve as binding partner to various proteins and are therefore
capable of regulating their biological activities. Discovering small-
molecule modulators, in particular stabilizers, of such complexes via
traditional screening approaches is a challenging task. Herein, we
pioneered the first application of dynamic combinatorial chemistry
(DCC) to a PPI target, to find modulators of 14-3-3 proteins.
Evaluation of the amplified hits from the DCC experiments for their
binding affinity via surface plasmon resonance (SPR), revealed that the
low-micromolar (KD 15−16 μM) acylhydrazones are 14-3-3/
synaptopodin PPI stabilizers. Thus, DCC appears to be ideally suited for the discovery of not only modulators but even the
more elusive stabilizers of notoriously challenging PPIs.
KEYWORDS: Protein−protein interactions, DCC, hit-identification strategy, small-molecule stabilizers
The family of 14-3-3 proteins is present in all eukaryoticcell types, and its members are involved in a myriad of
processes in the human body.1 They play significant roles,
ranging from signal transduction, to regulation of metabolism,
to cell-death, and they are correlated to diseases such as
Alzheimer’s and Noonan syndrome.2,3 This is attributed to the
ability of 14-3-3 to establish protein−protein interactions
(PPIs) with more than 500 protein partners.4 There are seven
known human isoforms of 14-3-3: beta (β), epsilon (ε), eta
(η), gamma (γ), tau (τ), sigma (σ), and zeta (ζ). The binding
partners feature three conserved binding motifs for the binding
groove in 14-3-3: RSXpSXP (mode 1), RXXXpSXP (mode 2),
and pS/TX-COOH (mode 3), where pS/T denotes a
phosphoserine or threonine residue.5−7 In this study, we
used the actin binding protein synaptopodin as a binding
partner of 14-3-3 using mode 2 for interaction. Synaptopodin
maintains the actin cytoskeleton and urine-filtering capabilities
of podocytes in the kidney glomerulus. It is regulated through
phosphorylation and subsequent 14-3-3 binding.8 14-3-3
proteins are potential drug targets and an increasing number
of chemical classes that modulate 14-3-3 PPIs have been
reported, as recently reviewed.9,10 Modulators of 14-3-3 PPIs
can be inhibitors, mostly small synthetic molecules, and
stabilizers, which include bigger scaffolds, e.g., pyrrolidone1
and (semi-) natural products, e.g., fusicoccin-A.9,11−14
Dynamic combinatorial chemistry (DCC) has become an
established technique for hit identification. Briefly, it allows a
target-based amplification of the best binder(s) from a pool of
reacting building blocks and the corresponding products
existing under thermodynamic equilibrium. The types of
reversible linkages that can be applied in DCC, reaction
conditions, and analysis of the dynamic combinatorial library
(DCL) have been comprehensively reviewed before.15−17 In
the present work, we set out to demonstrate the full potential
of DCC by pioneering its application to the hitherto
unexplored class of PPI target, thus we exploited the power
of DCC to identify new PPI modulators targeting the 14-3-
3(ζ) isoform. For the DCC experiments, we used acylhy-
drazone formation from the corresponding hydrazide and
aldehyde as a reversible reaction. The acylhydrazone linkage
can take part in binding with the desired target, as it offers H-
bond donor and -acceptor sites. The acylhydrazone formation
is sufficiently reversible in acidic media, but also stable against
hydrolysis.18 In basic media, the reaction is very slow, therefore
high pH values are used to freeze the equilibrium prior to DCL
analysis. Bhat et al. showed that the use of aniline can
accelerate the formation of the equilibrium to only 6 h while
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applying a closer to physiological pH of 6.2.19,20 As a
prerequisite for acylhydrazone-based DCC, we systematically
monitored the stability of our target protein 14-3-3(ζ) under
acidic conditions using different buffers and pH values.21 We
found that in MES buffer at pH 6.5, 14-3-3(ζ) is stable at room
temperature up to 7 days. Therefore, we selected these
conditions in the presence of 10 mM aniline as a nucleophilic
catalyst for the DCC experiments. In order to confirm that the
protein is folded correctly, we recorded the circular dichroism
(CD) of 14-3-3. The obtained CD-spectrum matches that
reported in the literature (Supporting Information, Figure
S4).22
■ RESULTS AND DISCUSSION
The initial design of the DCL and choice of building blocks
were inspired by compound 1, a small-molecule inhibitor of
14-3-3 discovered by virtual screening.23 We envisioned the
acylhydrazone linkage between the two aromatic rings,
resulting in compound 2 (Figure 1). This modification should
maintain the length of the linker between the two aromatic
moieties of 1 owing to the restricted flexibility of the
acylhydrazone group. Accordingly, compound 2 was synthe-
sized in three consecutive steps starting with a condensation
reaction between the commercially available 2-iodobenzhy-
drazide and 2,3-dichlorobenzaldehyde to form the acylhy-
drazone 3 (Scheme 1). A palladium-catalyzed coupling
between the aryl iodide 3 and triethyl phosphite followed, to
afford the phosphate ester 4. This was achieved by first
formation of a palladium phosphonate complex at 150 °C,
followed by the addition of the acylhydrazone 3 at 100 °C. It
was important to lower the temperature before adding the
acylhydrazone 3 in order to prevent its decomposition.
Deprotection of 4 was achieved by TMSBr, resulting in the
target compound 2. It is noteworthy that trials to prepare the
hydrazide building block with o-phosphonic acid moiety,
required for DCC, using the above-mentioned coupling
conditions were unsuccessful, and only an intramolecular N-
arylation product was obtained. We therefore had to use
compound 2 in our DCC experiments for in situ generation of
the corresponding hydrazide and aldehyde.
We evaluated compound 2 for its biochemical properties via
surface plasmon resonance (SPR) and fluorescence polar-
ization (FP) assay. For the SPR study, we first determined the
binding affinity (KD) of a synaptopodin fragment containing
the binding motif to 14-3-3(ζ). The 29-amino acid peptide
showed a clear binding response with the same KD value of
1.38 μM obtained from either the Langmuir isotherm or the
kinetic curves (Figure S7). This showed us that the
immobilized protein is still in the native folded state and can
engage in PPIs. Next, we assessed compound 2, which showed
low millimolar affinity (KD value 1.01 mM) toward 14-3-3(ζ)
(Figure 2). In the FP assay, compound 2 was titrated to fixed
concentrations of 14-3-3(ζ) and a fluorescently labeled 29-mer
peptide fragment of synaptopodin. A known 14-3-3 PPI
stabilizing molecule, fusicoccin-A, was used as a positive
control resulting in a dose-dependent increase in FP signal
(Figure S5). In agreement with our design approach, titrating
compound 2 to the protein−peptide complex decreases the
signal indicating an inhibitory effect with an EC50 value of 120
μM (Figure S5).
Encouraged by these results we designed a DCL based on
compound 2 (Figure 1 and Scheme S1). Besides the o-
phenylphosphonic acid moiety, we used diverse aryl-,
heteroaryl-, alicylic-, and alkylhydrazides to explore other
scaffolds for potential binding to 14-3-3(ζ). As an aldehyde
component, four building blocks with similar reactivity were
selected including haloaryl- and heteroarylaldehydes. However,
LC-MS analysis of the DCC experiment did not reveal all of
the possible acylhydrazones bearing o-phosphonic or o-sulfonic
acid moieties (Figure S1). We therefore modified the DCL to
include three aldehydes A1−A3 and six hydrazides H1−H6
and exclude the acidic motifs as shown in Scheme 2.
Consequently, we ran three DCC experiments: (a) a library
in which building blocks were present in combination with the
14-3-3(ζ)/unlabeled synaptopodin complex as a PPI model;
(b) a library containing the building blocks and 14-3-3 protein;
and (c) a “blank” in which only building blocks were present
(Scheme 2).
LC-MS analysis of the DCLs that were allowed to
equilibrate for 6 h resulted in the chromatograms shown in
Figure 3. The most obvious differences are the two peaks at
retention times of 13.5 and 13.9 min, corresponding to the
compounds A1H3 and A2H3, respectively. In the presence of
14-3-3(ζ) only and in the PPI-complex (14-3-3(ζ)/synapto-
podin), these two acylhydrazones show a significant
amplification (about 148%) compared to the DCL in the
absence of protein. Table 1 shows the ratios of the relative
areas of each peak compared to the blank DCL. These two hits
were then synthesized to confirm the identity of peaks (Figure
S3) and for biochemical characterization.
Synthesis was accomplished through the reaction of the
hydrazide H3 with a stoichiometric amount of the appropriate
aldehyde at reflux overnight to afford the corresponding
acylhydrazones in good to quantitative yield (Scheme 3).
We used SPR binding assays to analyze binding events
(affinity and binding kinetics) of the synthesized DCC hits to
the 14-3-3(ζ) protein. The acylhydrazones A1H3 and A2H3
Figure 1. Design of DCL for 14-3-3 PPIs modulation based on the
known small-molecule inhibitor 1.
Scheme 1. Synthetic Route toward Compound 2
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showed low micromolar affinity to 14-3-3(ζ) (KD values 16
and 15 μM, respectively). Interestingly, compound A2H3
exhibited different on- and off-rates with a longer residence
time compared to A1H3 although with equal binding affinities
(Table 2, Figure S8 and S9).
Intrigued by these findings, we next investigated the
mechanism of action and binding site of the new 14-3-3 PPI
modulators (compounds 2, A1H3, and A2H3) by SPR
competition assays using synaptopodin as a reference, which
occupies the 14-3-3 main binding pocket. Modulators that
inhibit 14-3-3 PPIs bind in the phosphorylation binding
pocket, whereas stabilizers bind allosterically to the binding
pocket or at the interface between 14-3-3 and its protein
partners.24 To check whether the compounds bind to the
active site or elsewhere, we injected compound 2 (1000 μM),
synaptopodin (1 μM), and a mixture of both at the same
concentration in sequence over immobilized 14-3-3(ζ). The
obtained response unit (RU) value of the mixture was
compared to the theoretical sum of the RU values for the
individual compounds. If 2 bound to the main binding pocket
of 14-3-3, it would compete with synaptopodin and the
response of the mixture should be less than the sum of RU
values determined for the single compounds. On the other
hand, if 2 bound allosterically to the active site, no competition
Figure 2. SPR binding assay of 2: (a) Overlay of sensorgrams (black) of 2 at concentrations of 1.6−1000.0 μM running over an immobilized 14-3-
3(ζ). Global fitting of the association and dissociation curves (red), (b) Langmuir binding isotherm (KD = 1.01 ± 0.03 mM). Data obtained from
single experiment.
Scheme 2. Dynamic Combinatorial Library (DCL) of
Acylhydrazones with Aldehydes (100 μM Each), Hydrazides
(300 μM Each), DMSO (5%), Aniline (10 mM), and (a) 14-
3-3(ζ) (10 μM) and Synaptopodin (10 μM); (b) Control
with 14-3-3(ζ) (10 μM); and (c) Control without Protein or
Synaptopodin
Figure 3. UV-chromatograms at 290 nm of DCLs in duplicate, blank (B), in the presence of protein (P), and in the presence of protein plus
synaptopodin (PS) after 6 h. Compounds A1H3 and A2H3 are amplified in P as well as PS compared to B.
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would occur and the response of the mixture should be equal
to the sum of RU values of the individual compounds. We
found that the RU value of 2 in combination with
synaptopodin was less than the sum of the individual responses
(Figure 4 and S10). This suggests that compound 2 competes
with synaptopodin for the same binding pocket. No
compound, however, could completely displace the other at
the tested concentrations. To verify this, we recalculated the
sum of responses considering a fractional occupancy (FO) of 2
and synaptopodin according to Perspicace et al.25 Indeed, the
experimental RU value of the mixture was equal to the new
estimated one (Figure 4), indicating that the compounds
compete for the same binding site. Using different concen-
trations of 2 and synaptopodin (1000 μM vs 25 μM; and 200
μM vs 1 μM) afforded the same results (Figure S11 and S12).
In line with the FP-assay data, these results clearly indicate that
compound 2 binds to the active site of 14-3-3, leading to
disruption of PPIs.
Using the same approach, we injected the DCC hit
compounds A1H3 (25 μM) and A2H3 (25 μM) alone and
as a mixture with synaptopodin (1 μM) over immobilized 14-
3-3, and analyzed their binding responses (Figure 5).
Interestingly, the RU values of the mixtures containing
A1H3 or A2H3 with synaptopodin were equal to or more
than the sum of the individual responses (Figure 4 and 5). This
indicates that these two compounds bind to 14-3-3 in a
different pocket than that of synaptopodin. Moreover, the
increased binding response of the mixture compared to the
calculated sum indicates a stabilizing effect of the acylhy-
drazones to the complex of synaptopodin with 14-3-3(ζ). This
confirms our findings from the DCC experiments, where the
same amplification factors for these hits were obtained in the
presence of 14-3-3(ζ) alone as well as the 14-3-3(ζ)/
synaptopodin complex (Table 1). Therefore, their binding
site could be allosteric to the main binding pocket, e.g. at the
interface of the 14-3-3(ζ)/synaptopodin complex.
■ CONCLUSIONS
We set out to develop novel PPI modulators targeting the
versatile 14-3-3 protein family. First, we pursued a ligand-based
design of the acylhydrazone 2, which turned out to be an
inhibitor of 14-3-3 PPIs. Next, we applied a DCC approach,
using 14-3-3(ζ) in complex with synaptopodin as a PPI model,
resulting in the discovery of two modulators A1H3 and A2H3.
No significant change was observed in the DCL composition in
the presence of only 14-3-3 compared to the 14-3-3(ζ)/
synaptopodin complex, indicating that the hit compounds bind
independently to a different site than the main binding groove
Table 1. Amplification Factors of the Products Formed in
the DCC Experiments Analyzed via the Relative Areas of





in the presence of
14-3-3c
% Amplification in the
presence of 14-3-3−
synaptopodin complexd
A3H2 4.76 −59.0 −44.0
A3H4 5.66 −33.9 −35.9
A3H6 6.62 −25.7 −16.4
A3H1 7.93 −33.1 −18.1
A1H2, A3H5 8.21 −32.3 −35.1
A2H2, A1H4 9.09 −28.0 −26.0
A2H4 9.73 −36.7 −32.9
A1H1, A1H6 10.66 −20.4 −23.1
A3H3 10.79 −1.3 −15.0
A2H6 11.29 −22.5 −23.6
A2H1 11.49 32.2 29.5
A1H5 11.91 −12.2 −16.0
A2H5 12.49 12.8 14.6
A1H3 13.46 148.0 148.4
A2H3 13.91 148.5 153.6
aValues represent the average of two independent experiments.
bRetention time. cCalculated as ( )100%RPAprotein RPAblankRPAblank ×− . dCal-
culated as ( )100%RPAcomplex RPAblankRPAblank ×− .
Scheme 3. Synthetic Route toward Compounds A1H3 and
A2H3
Table 2. Kinetic Parameters of Hit Compounds A1H3 and A2H3 to 14-3-3(ζ)a
Compd Rmax (RU) kon (M
−1s−1) koff (s
−1) t1/2 (s) KD (μM)
A1H3 4.6 ± 0.2 2.6 ± 0.2 × 103 4.1 ± 0.1 × 10−2 17 16 ± 1
A2H3 4.5 ± 0.2 5.8 ± 0.5 × 102 8.7 ± 0.4 × 10−3 80 15 ± 1
aRmax: maximum analyte binding capacity; kon: association rate constant; koff: dissociation rate constant; t1/2: dissociative half-life; KD: equilibrium
dissociation constant.
Figure 4. SPR responses of compounds 2, A1H3, and A2H3 in the
competition assays, using synaptopodin as a reference compound
binding to the active site of 14-3-3.
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of 14-3-3 involved in PPIs. Finally, we determined the binding
affinities and kinetics of the hits via SPR and investigated their
binding site on 14-3-3. Results of the SPR competition assays
support our initial findings from the DCC experiments,
suggesting that these small molecules stabilize the 14-3-3(ζ)/
synaptopodin complex either directly or allosterically.
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